DexCom (NASDAQ:DXCM) Price Target Raised to $93.00 at Barclays

DexCom (NASDAQ:DXCM) had its price objective upped by Barclays from $90.00 to $93.00 in a research report report published on Monday,Benzinga reports. They currently have an equal weight rating on the medical device company’s stock.

Several other equities analysts have also issued reports on DXCM. Piper Sandler decreased their price objective on DexCom from $100.00 to $90.00 and set an “overweight” rating for the company in a research report on Friday. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Mizuho began coverage on DexCom in a report on Thursday, April 10th. They issued an “outperform” rating and a $85.00 price target on the stock. Canaccord Genuity Group increased their price objective on DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a report on Friday. Finally, Cfra Research upgraded DexCom to a “hold” rating in a research note on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $98.11.

DexCom Stock Down 1.7 %

Shares of NASDAQ:DXCM opened at $80.27 on Monday. The company has a market capitalization of $31.47 billion, a PE ratio of 56.13, a P/E/G ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company’s fifty day moving average is $71.27 and its 200-day moving average is $76.93. DexCom has a 52 week low of $57.52 and a 52 week high of $132.26.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the company earned $0.32 EPS. The firm’s revenue was up 12.5% compared to the same quarter last year. Equities research analysts predict that DexCom will post 2.03 earnings per share for the current fiscal year.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 13,000 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the transaction, the executive vice president now owns 105,602 shares in the company, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares of the company’s stock, valued at approximately $10,002,636.06. The trade was a 4.91 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,926 shares of company stock worth $4,734,384. 0.32% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DXCM. Wilmington Savings Fund Society FSB bought a new position in shares of DexCom during the third quarter valued at approximately $381,000. B. Riley Wealth Advisors Inc. grew its position in DexCom by 42.3% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 5,590 shares of the medical device company’s stock valued at $370,000 after acquiring an additional 1,662 shares during the last quarter. Versant Capital Management Inc purchased a new stake in DexCom in the fourth quarter worth $25,000. Nordea Investment Management AB lifted its position in shares of DexCom by 2.8% during the fourth quarter. Nordea Investment Management AB now owns 80,590 shares of the medical device company’s stock worth $6,271,000 after purchasing an additional 2,183 shares during the last quarter. Finally, First Hawaiian Bank boosted its stake in shares of DexCom by 556.1% during the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company’s stock valued at $1,801,000 after purchasing an additional 19,629 shares during the period. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.